Education, 2018

LETI launches its 2nd edition of Medtech Entrepreneur-In-Residence Programme

14th August 2019

Leti is targeting segments aligned with medical, industrial and societal needs

Leti, a technological research institute at CEA Tech which has launched more than 60 start-ups and is an EIT Health Partner, has created a Medtech Entrepreneur-In-Residence programme to help bring to market creative devices and solutions that will address tomorrow’s healthcare challenges.

The first edition has led to the selection of a project focusing on IoT for Healthcare in collaboration with a senior medtech engineer and a clinician. The project is currently in the incubation phase. Entrepreneurs who qualify to join the programme will have access to Leti’s state-of-the-art technological, preclinical and clinical platforms and its knowhow to design and create products or solutions and launch disruptive start-ups.

Leti’s global approach to developing medical technology is the result of the excellence, expertise and multidisciplinary approach of its researchers, its infrastructure and its strong relationships with leading medical-industry partners. For the programme’s second participation challenge, Leti is targeting segments aligned with medical, industrial and societal needs.

These include:

  • Point-of-Care diagnosis,
  • Internet of Things for healthcare, from prevention to treatment,
  • Medical devices for innovative therapies such as drug delivery, physical effectors and bioelectronics.
  • And medical devices for exposome monitoring (environmental exposure)
  • Selected entrepreneurs will benefit from incubation periods of six to 12 months that includes:
  1. Access to Leti’s research teams, laboratories and technical expertise (state-of-the-art clean-rooms, photonics, biological, chemistry, microfluidic, electronic, modeling, characterisation, clinical and pre-clinical facilities)
  2. Identification of relevant Intellectual Property from Leti’s portfolio of 2,760 patents
  3. Resources for the joint development of an IP-based proof-of-concept for the target market and application
  4. Access to Leti’s start-up programme, and potentially to its partners’ mentorship programmes, on a case-by-case basis.

Applications are expected by 1 December 2018.

Downlod the application form below.

For further enquiries contact:

  • Philippe Ruffin, joins forces with La Roche-Posay joins forces with La Roche-Posay

Discover how the partnership will benefit patients

Find out more

Leuko closes €5M Series A round

Leuko closes €5M Series A round

Learn more about Leuko and its achievements

Find out more

EIT Health appoints three new Supervisory Board members

EIT Health appoints three new Supervisory Board members

Join us in welcoming our new Board members

Find out more